Seagen, a wholly owned subsidiary of Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Seagen, a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Seagen, a wholly owned subsidiary of Pfizer: 28 sponsored US clinical trials, 7 recruiting.
Seagen, a wholly owned subsidiary of Pfizer sponsors 28 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 5 completed. 7 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Non-Small Cell Lung, with 9 trials.
Top-decile sponsor footprint
Seagen, a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
28 total, page 1 of 1
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
NCT06254495
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03786081
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
NCT06120504
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
NCT05902494
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT05194072
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
NCT04539938
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
NCT04569032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 9 |
| Phase 3 | 7 |
Therapeutic Areas
What is open in the Seagen, a wholly owned subsidiary of Pfizer pipeline
7 recruiting of 28 indexed (25% open); 5 completed (18%).
Phase mix: 7 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Non-Small Cell Lung (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Seagen, a wholly owned subsidiary of Pfizer: open-pipeline peers nationwide
Peers matched on 28 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Seagen, a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 trials (± recruiting share)
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
Related
What to do with this Seagen, a wholly owned subsidiary of Pfizer page
28 registered trials is a research-attention snapshot, not an endorsement of Seagen, a wholly owned subsidiary of Pfizer or any single study.
- 7 of Seagen, a wholly owned subsidiary of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Carcinoma, Non-Small Cell Lung is the condition Seagen, a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Non-Small Cell Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Seagen, a wholly owned subsidiary of Pfizer pipeline card: 28 registered trials from official public datasets.Report a data error.